Intravitreal tissue plasminogen activator for the treatment of central retinal vein occlusion.
A 58-year-old hypertensive man with a perfused central retinal vein occlusion of 21 days' duration received 50 microg of intravitreal recombinant tissue plasminogen activator in 0.1 cc. Best-corrected visual acuity improved 2 weeks after the injection. Optical coherence tomography and fluorescein angiography demonstrated resolution of cystoid macular edema and improvement of venous outflow. Intravitreal tissue plasminogen activator may be a useful treatment for central retinal vein occlusion with a duration of 21 days or less.
Weizer
Jennifer S
JS
Duke University Eye Center, Durham, North Carolina 27710, USA.
Fekrat
Sharon
S
D005451:Fluorescein Angiography; D005654:Fundus Oculi; D006801:Humans; D008269:Macular Edema / Q000150:complications; D008297:Male; D008875:Middle Aged; D009887:Ophthalmoscopy; D055095:Optics and Photonics; D012170:Retinal Vein Occlusion / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D014054:Tomography; D014792:Visual Acuity; D014822:Vitreous Body
D010959:Tissue Plasminogen Activator